PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt’s lymphoma and other highly proliferative malignant cells

Blood Cells, Molecules, and Diseases

Volumn 27, Issue 5, 2001, Pages 825-829

  Simons Evelyn, Michelle ^a   Bailey Dell, Kim ^a   Toretsky, Jeffrey A ^a   Ross, Douglas D ^a   Fenton, Robert ^a   Kalvakolanu, Dhan ^a   Rapoport, Aaron P ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Burkitt s lymphoma; Mitotic kinase; PBK TOPK; Serine threonine kinases

Indexed keywords

MESSENGER RNA; PDZ BINDING KINASE; PDZ-BINDING KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASES; PROTEIN PBK TOPK; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD CELL; BURKITT LYMPHOMA; CELL CULTURE; CYTOLOGY; ENZYMOLOGY; FETUS; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TONSIL; UPREGULATION; ACUTE LYMPHOCYTIC LEUKEMIA; B LYMPHOCYTE ACTIVATION; BRAIN; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME REGULATION; FETUS DEVELOPMENT; HUMAN CELL; KIDNEY; LEUKEMIA; LUNG; LYMPHOMA; MITOSIS; MOLECULAR CLONING; MYELOMA; NORTHERN BLOTTING; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RELAPSE; RNA ANALYSIS; SPLEEN; TESTIS; TISSUE DISTRIBUTION; TONSIL CELL;

ADULT; B-LYMPHOCYTES; BLOOD CELLS; BURKITT LYMPHOMA; FETUS; HUMAN; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; TONSIL; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0035210934     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.2001.0452     Document Type: Article

References (10)

1. Identification of differentially expressed genes in a human Burkitt’s lymphoma cell line using differential mRNA display
2. Characterization of PDZ-binding kinase, a mitotic kinase
3. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells
4. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death
5. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma
6. Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers
7. Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin’s lymphoma: Independent prognostic value of p27Kipl
8. Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt’s lymphoma cell line containing mutant p53 genes
9. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
10. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status